Boston Scientific to acquire Penumbra: $374 cash or 3.8721 BSX shares per share; 73% cash/27% stock

Penumbra Inc

Penumbra holders elect $374 cash or 3.8721 BSX shares per share; proration targets 73.26% cash/26.74% stock.
Termination: Penumbra pays $525M if it accepts superior offer; Boston Sci pays $900M if antitrust fails.
Closing subject to Penumbra stockholder vote, HSR and foreign antitrust clearance, S-4 effectiveness, NYSE listing.
Preliminary Q4/FY2025 results released; audited financials pending, specific figures not in filing.

item 1.01 item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Penumbra Inc entered into Agreement and Plan of Merger with Boston Scientific Corporation (effective 2026-01-14).

Action: entry
Agreement: merger
Counterparty: Boston Scientific Corporation
Effective: 2026-01-14

Exact text from the filing

On January 14, 2026, Penumbra, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) among the Company, Boston Scientific Corporation, a Delaware corporation (“Parent”), and Pinehurst Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Parent.

View on SEC.gov

Browse all material agreements →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0000950103-26-000523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.